TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,757,597 | -57.7% | 308,456 | -27.3% | 0.00% | -33.3% |
| Q2 2023 | $6,520,949 | -39.2% | 424,541 | -11.0% | 0.00% | -50.0% |
| Q1 2023 | $10,723,413 | +84.5% | 476,808 | +72.5% | 0.01% | +100.0% |
| Q4 2022 | $5,813,260 | -28.0% | 276,427 | -15.7% | 0.00% | -40.0% |
| Q3 2022 | $8,077,000 | -38.9% | 327,833 | -39.9% | 0.01% | -28.6% |
| Q2 2022 | $13,210,000 | -10.7% | 545,234 | -5.0% | 0.01% | 0.0% |
| Q1 2022 | $14,794,000 | +19.9% | 574,044 | +44.4% | 0.01% | +16.7% |
| Q4 2021 | $12,343,000 | +49.3% | 397,646 | +16.7% | 0.01% | +50.0% |
| Q3 2021 | $8,266,000 | +65.7% | 340,847 | -0.3% | 0.00% | +100.0% |
| Q2 2021 | $4,989,000 | -55.3% | 341,929 | -23.4% | 0.00% | -66.7% |
| Q1 2021 | $11,151,000 | -7.9% | 446,569 | +0.5% | 0.01% | -14.3% |
| Q4 2020 | $12,108,000 | – | 444,281 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |